Currently, there are 166.35M common shares owned by the public and among those 164.30M shares have been available to trade.
The company’s stock has a 5-day price change of -1.07% and 8.52% over the past three months. ACAD shares are trading -46.69% year to date (YTD), with the 12-month market performance down to -46.82% lower. It has a 12-month low price of $14.15 and touched a high of $31.92 over the same period. ACAD has an average intraday trading volume of 1.43 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.08%, 1.64%, and 1.70% respectively.
Institutional ownership of Acadia Pharmaceuticals Inc (NASDAQ: ACAD) shares accounts for 93.77% of the company’s 166.35M shares outstanding.
It has a market capitalization of $2.71B and a beta (3y monthly) value of 0.40. The stock’s trailing 12-month PE ratio is 21.61, while the earnings-per-share (ttm) stands at $0.77. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.87% over the week and 4.14% over the month.
Earnings per share for the fiscal year are expected to increase by 293.22%, and 6.41% over the next financial year.
Morgan Stanley coverage for the Acadia Pharmaceuticals Inc (ACAD) stock in a research note released on August 07, 2024 offered a Equal-Weight rating with a price target of $20. BMO Capital Markets was of a view on June 27, 2024 that the stock is Outperform, while Needham gave the stock Buy rating on March 12, 2024, issuing a price target of $36- $32. Mizuho on their part issued Neutral rating on March 12, 2024.
